PDE5A and pulmonary arterial hypertension: In addition, the AMBITION trial showed that dual combination therapy with Ambrisentan and Tadalafil, a PDE-5 inhibitor, reduced the risk of PAH-related hospitalization by 63% compared with just monotherapy (80).